• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

在美国癌症联合委员会（第 8 版）胰腺癌分期系统中，III 期应进一步细分为 IIIA 期和 IIIB 期。

Stage III should be subclassified into Stage IIIA and IIIB in the American Joint Committee on Cancer (8 Edition) staging system for pancreatic cancer.

机构信息

Department of General Surgery, Tianjin First Central Hospital, Tianjin 300192, China.

Department of Surgery, Tianjin Second People's Hospital, Tianjin 300192, China.

出版信息

World J Gastroenterol. 2018 Jun 14;24(22):2400-2405. doi: 10.3748/wjg.v24.i22.2400.

DOI:10.3748/wjg.v24.i22.2400
PMID:29904247
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6000291/
Abstract

AIM

To ascertain the prognostic role of the T4 and N2 category in stage III pancreatic cancer according to the 8 edition of the American Joint Committee on Cancer (AJCC) classification.

METHODS

Patients were collected from the Surveillance Epidemiology and End Results (SEER) database (2004-2013) and were divided into three groups: T(1-3)N2, T4N(0-1), and T4N2. Overall survival (OS) and disease-specific survival (DSS) of patients were evaluated by the Kaplan-Meier method.

RESULTS

For the first time, we found a significant difference in OS and DSS between T(1-3)N2/T4N(0-1) and T4N2 but not between T(1-3)N2 and T4N(0-1). A higher grading correlated with a worse prognosis in the T(1-3)N2 and T4N2 groups.

CONCLUSION

Patients with stage T4N2 had a worse prognosis than those with stage T(1-3)N2/T4N(0-1) in the 8 edition AJCC staging system for pancreatic cancer. We recommend that stage III should be subclassified into stage IIIA [T(1-3)N2/T4N(0-1)] and stage IIIB (T4N2).

摘要

目的

根据第 8 版美国癌症联合委员会（AJCC）分类，确定 T4 和 N2 分期在 III 期胰腺癌中的预后作用。

方法

从监测、流行病学和最终结果（SEER）数据库（2004-2013 年）中收集患者，并将其分为三组：T（1-3）N2、T4N（0-1）和 T4N2。通过 Kaplan-Meier 法评估患者的总生存率（OS）和疾病特异性生存率（DSS）。

结果

我们首次发现 OS 和 DSS 在 T（1-3）N2/T4N（0-1）和 T4N2 之间存在显著差异，但在 T（1-3）N2 和 T4N（0-1）之间无差异。较高的分级与 T（1-3）N2 和 T4N2 组的预后较差相关。

结论

在第 8 版 AJCC 胰腺癌分期系统中，T4N2 期患者的预后比 T（1-3）N2/T4N（0-1）期患者差。我们建议将 III 期进一步细分为 IIIA 期[T（1-3）N2/T4N（0-1）]和 IIIB 期（T4N2）。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eacb/6000291/06ea452c9988/WJG-24-2400-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eacb/6000291/98dd8bf492d7/WJG-24-2400-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eacb/6000291/06ea452c9988/WJG-24-2400-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eacb/6000291/98dd8bf492d7/WJG-24-2400-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eacb/6000291/06ea452c9988/WJG-24-2400-g002.jpg

相似文献

1
Stage III should be subclassified into Stage IIIA and IIIB in the American Joint Committee on Cancer (8 Edition) staging system for pancreatic cancer.在美国癌症联合委员会（第 8 版）胰腺癌分期系统中，III 期应进一步细分为 IIIA 期和 IIIB 期。
World J Gastroenterol. 2018 Jun 14;24(22):2400-2405. doi: 10.3748/wjg.v24.i22.2400.
2
Evaluation of the prognostic value of the new AJCC 8th edition staging system for patients with pancreatic adenocarcinoma; a need to subclassify stage III?评估新版 AJCC 8 分期系统对胰腺腺癌患者的预后价值；是否需要对 III 期进行亚分类？
Eur J Cancer. 2018 Nov;104:62-69. doi: 10.1016/j.ejca.2018.08.027. Epub 2018 Oct 13.
3
Evaluation of the 8th AJCC staging system for pathologically versus clinically staged pancreatic adenocarcinoma: A time to revisit a dogma?评估第 8 版 AJCC 病理分期与临床分期系统在胰腺腺癌中的应用：是否需要重新审视这一传统观点？
Hepatobiliary Pancreat Dis Int. 2018 Feb;17(1):64-69. doi: 10.1016/j.hbpd.2018.01.014. Epub 2018 Jan 31.
4
Validation of the American Joint Committee on Cancer 8th edition staging system for the pancreatic ductal adenocarcinoma.验证美国癌症联合委员会第 8 版胰腺导管腺癌分期系统。
Eur J Surg Oncol. 2019 Nov;45(11):2159-2165. doi: 10.1016/j.ejso.2019.06.002. Epub 2019 Jun 3.
5
Validation of the eighth edition of the AJCC staging system for patients with pancreatic adenocarcinoma initially receiving chemoradiotherapy and proposal of modifications.验证第八版 AJCC 分期系统在最初接受放化疗的胰腺腺癌患者中的应用，并提出修改建议。
Cancer Biol Med. 2020 May 15;17(2):492-500. doi: 10.20892/j.issn.2095-3941.2019.0101.
6
Challenging a dogma; AJCC 8th staging system is not sufficient to predict outcomes of patients with malignant pleural mesothelioma.挑战传统观念；第 8 版 AJCC 分期系统不足以预测恶性胸膜间皮瘤患者的预后。
Lung Cancer. 2017 Nov;113:128-133. doi: 10.1016/j.lungcan.2017.09.015. Epub 2017 Oct 3.
7
Application of the Eighth Edition of the American Joint Committee on Cancer Staging for Pancreatic Adenocarcinoma.美国癌症联合委员会第八版胰腺癌分期系统的应用
Pancreas. 2018 Jul;47(6):742-747. doi: 10.1097/MPA.0000000000001073.
8
Validation of the American Joint Commission on Cancer (AJCC) 8th Edition Staging System for Patients with Pancreatic Adenocarcinoma: A Surveillance, Epidemiology and End Results (SEER) Analysis.美国癌症联合委员会（AJCC）第8版胰腺癌患者分期系统的验证：一项监测、流行病学和最终结果（SEER）分析。
Ann Surg Oncol. 2017 Jul;24(7):2023-2030. doi: 10.1245/s10434-017-5810-x. Epub 2017 Feb 17.
9
Mesenterico-portal vein invasion should be an important factor in TNM staging for pancreatic ductal adenocarcinoma: Proposed modification of the 8 edition of the American Joint Committee on Cancer staging system.肠系膜门静脉侵犯应成为胰腺导管腺癌 TNM 分期的一个重要因素：美国癌症联合委员会第 8 版分期系统的修改建议。
World J Gastroenterol. 2019 Dec 14;25(46):6752-6766. doi: 10.3748/wjg.v25.i46.6752.
10
Modified Staging Classification for Pancreatic Neuroendocrine Tumors on the Basis of the American Joint Committee on Cancer and European Neuroendocrine Tumor Society Systems.基于美国癌症联合委员会和欧洲神经内分泌肿瘤学会系统的胰腺神经内分泌肿瘤改良分期分类。
J Clin Oncol. 2017 Jan 20;35(3):274-280. doi: 10.1200/JCO.2016.67.8193. Epub 2016 Sep 30.

引用本文的文献

1
A DNA-Methylation-Driven Genes Based Prognostic Signature Reveals Immune Microenvironment in Pancreatic Cancer.基于 DNA 甲基化驱动基因的预后标志物揭示了胰腺癌中的免疫微环境。
Front Immunol. 2022 Feb 10;13:803962. doi: 10.3389/fimmu.2022.803962. eCollection 2022.
2
Pancreatic surgery: we need clear definitions.胰腺手术：我们需要明确的定义。
Langenbecks Arch Surg. 2019 Mar;404(2):159-165. doi: 10.1007/s00423-018-1725-7. Epub 2018 Nov 6.

本文引用的文献

1
Validation of the American Joint Commission on Cancer (AJCC) 8th Edition Staging System for Patients with Pancreatic Adenocarcinoma: A Surveillance, Epidemiology and End Results (SEER) Analysis.美国癌症联合委员会（AJCC）第8版胰腺癌患者分期系统的验证：一项监测、流行病学和最终结果（SEER）分析。
Ann Surg Oncol. 2017 Jul;24(7):2023-2030. doi: 10.1245/s10434-017-5810-x. Epub 2017 Feb 17.
2
A perspective on cancer cell metastasis.癌症细胞转移的观点。
Science. 2011 Mar 25;331(6024):1559-64. doi: 10.1126/science.1203543.
3
Pancreatic cancer.
胰腺癌
N Engl J Med. 2010 Apr 29;362(17):1605-17. doi: 10.1056/NEJMra0901557.
4
The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM.美国癌症联合委员会：第 7 版 AJCC 癌症分期手册与 TNM 的未来。
Ann Surg Oncol. 2010 Jun;17(6):1471-4. doi: 10.1245/s10434-010-0985-4.
5
Pancreatic adenocarcinoma: the actual 5-year survivors.胰腺腺癌：真正的5年生存者。
J Gastrointest Surg. 2008 Apr;12(4):701-6. doi: 10.1007/s11605-007-0384-8. Epub 2007 Nov 20.
6
Impact of total lymph node count and lymph node ratio on staging and survival after pancreatectomy for pancreatic adenocarcinoma: a large, population-based analysis.总淋巴结计数和淋巴结比率对胰腺腺癌胰十二指肠切除术后分期及生存的影响：一项基于人群的大型分析
Ann Surg Oncol. 2008 Jan;15(1):165-74. doi: 10.1245/s10434-007-9587-1. Epub 2007 Sep 26.
7
Validation of the 6th edition AJCC Pancreatic Cancer Staging System: report from the National Cancer Database.美国癌症联合委员会（AJCC）第6版胰腺癌分期系统的验证：来自国家癌症数据库的报告
Cancer. 2007 Aug 15;110(4):738-44. doi: 10.1002/cncr.22852.
8
Surgical treatment of pancreatic adenocarcinoma; actual survival and prognostic factors in 343 patients.胰腺腺癌的外科治疗；343例患者的实际生存率及预后因素
Eur J Cancer. 2004 Mar;40(4):549-58. doi: 10.1016/j.ejca.2003.10.026.
9
The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited.癌症转移的发病机制：重温“种子与土壤”假说
Nat Rev Cancer. 2003 Jun;3(6):453-8. doi: 10.1038/nrc1098.
10
Pancreatic cancer biology and genetics.胰腺癌生物学与遗传学
Nat Rev Cancer. 2002 Dec;2(12):897-909. doi: 10.1038/nrc949.